MarketCap
Facebook
X
Telegram
Danimer Scientific Balance Sheet 2023-2011 | DNMR
Brief overview of Danimer Scientific's balance sheet strength
The comparison uses five available annual reports from the 2019–2023 interval.
The asset base grew from $144.6 million to $698.1 million, or +382.9%. Average annual growth of roughly 48.2% was strong.
Liability growth of +228.2% trailed asset growth of +382.9%. The funding structure became more resilient.
Shareholders' equity accounts for 39.8% of assets, previously 11.5%. Dependence on liabilities is moderate.
Net debt to equity stands at 1.3x; debt servicing is an important part of overall resilience.
The cash reserve occupies 8.5% of the balance sheet, previously 4.3%. It is one marker of short-term resilience.
Retained earnings remain negative at -$454.1 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall assessment
Danimer Scientific's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet Danimer Scientific
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
362 M | 239 M | -11.3 M | -314 M | 84.8 M | - | - | - | - | - | - | - | - |
Long Term Debt |
417 M | 298 M | 272 M | 60.5 M | 88.5 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
3.34 M | 3.34 M | 3.34 M | 3 M | 2.58 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 93.7 M | - | - | - | - | - | - | - | - |
Total Current Liabilities |
15.7 M | 25.3 M | 43.5 M | 50.5 M | 34.3 M | - | - | - | - | - | - | - | - |
Total Liabilities |
420 M | 335 M | 338 M | 190 M | 128 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
1 M | - | 214 K | 2.46 M | 4.58 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-454 M | -299 M | -119 M | -58.8 M | -49.9 M | - | - | - | - | - | - | - | - |
Total Assets |
698 M | 712 M | 839 M | 546 M | 145 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
59.2 M | 62.8 M | 286 M | 378 M | 6.26 M | 6.55 M | - | - | - | - | - | - | - |
Book Value |
278 M | 378 M | 500 M | 356 M | 16.6 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
278 M | 378 M | 500 M | 356 M | 16.6 M | 26.3 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Danimer Scientific
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
414 M | 423 M | 417 M | 417 M | 417 M | 418 M | 423 M | 298 M | 298 M | 274 M | 272 M | 272 M | 29.5 M | 29.6 M | 31.3 M | 31.4 M | 60.5 M | 31.4 M | 31.4 M | 88.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
432 M | 433 M | 433 M | 420 M | 417 M | 414 M | 423 M | 335 M | 342 M | 319 M | 325 M | 338 M | 121 M | 139 M | 230 M | 190 M | 190 M | 190 M | 190 M | 128 M | 56.9 K | 56.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
914 K | 850 K | 1.15 M | 1 M | - | - | - | - | 2 M | 2.29 M | 214 K | 214 K | 233 K | 822 K | 2.34 M | 2.46 M | 2.46 M | 2.46 M | 2.46 M | 4.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-526 M | -504 M | -481 M | -454 M | -415 M | -375 M | -335 M | -299 M | -271 M | -176 M | -145 M | -119 M | -106 M | -114 M | -154 M | -58.8 M | -58.8 M | -58.8 M | -58.8 M | -49.9 M | -3.98 K | -3.98 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
644 M | 667 M | 689 M | 698 M | 721 M | 744 M | 779 M | 712 M | 733 M | 791 M | 812 M | 839 M | 650 M | 646 M | 512 M | 546 M | 546 M | 546 M | 546 M | 145 M | 78 K | 78 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
22.2 M | 40.3 M | 57.3 M | 59.2 M | 77.4 M | 90.8 M | 102 M | 64.4 M | 99.1 M | 140 M | 210 M | 287 M | 194 M | 416 M | 313 M | 380 M | 378 M | 378 M | 378 M | 6.26 M | 20 K | 20 K | - | 6.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
212 M | 234 M | 256 M | 278 M | 304 M | 330 M | 356 M | 378 M | 392 M | 472 M | 488 M | 500 M | 529 M | 507 M | 282 M | 356 M | 356 M | 356 M | 356 M | 16.6 M | 21 K | 21 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
212 M | 234 M | 256 M | 278 M | 304 M | 330 M | 356 M | 378 M | 392 M | 472 M | 488 M | 500 M | 529 M | 507 M | 282 M | 356 M | 356 M | 356 M | 356 M | 16.6 M | 21 K | 21 K | - | 26.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Danimer Scientific, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.